Daniel Ceballos
A5051728887- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Diagnosis and treatment of tuberculosis
- Autoimmune and Inflammatory Disorders
- Gut microbiota and health
- Mycobacterium research and diagnosis
- Ferroptosis and cancer prognosis
- Tuberculosis Research and Epidemiology
- Pancreatic and Hepatic Oncology Research
- Adolescent and Pediatric Healthcare
- Gastric Cancer Management and Outcomes
- Liver Disease Diagnosis and Treatment
- Esophageal and GI Pathology
- Diverticular Disease and Complications
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Anorectal Disease Treatments and Outcomes
- Medical and Biological Ozone Research
- Gallbladder and Bile Duct Disorders
- Helicobacter pylori-related gastroenterology studies
- Immunodeficiency and Autoimmune Disorders
- Infectious Diseases and Tuberculosis
- Lipid metabolism and disorders
- Hydrogen's biological and therapeutic effects
Hospital Universitario de Gran Canaria Doctor Negrín
2016-2025
Hospital General Universitario Gregorio Marañón
2024
Hospital Universitari Germans Trias i Pujol
2019
Hôpital Lyon Sud
2013
Hospital Clínico Universitario Lozano Blesa
2007
Hospital de Sagunto
2007
Leitat Technological Center
2007
Hospital Universitario Insular de Gran Canaria
2007
The aims of this study were to assess the risk relapse after discontinuation anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), identify factors associated relapse, and evaluate overcome retreatment same anti-TNF those who relapsed.This was a retrospective, observational, multicenter study. IBD had been treated anti-TNFs whom these discontinued clinical remission achieved included.A total 1,055 included. incidence rate 19% 17% per patient-year...
Abstract Background Ulcerative colitis (UC) is a chronic inflammatory disorder characterized by periods of relapse and remission. Current treatment options aim to achieve mucosal healing sustain long-term remission, yet many patients experience failure. Filgotinib (FIL), selective JAK1 inhibitor, has emerged as promising therapeutic agent in UC management with favorable outcomes clinical trials. This study aimed evaluate the real-world efficacy safety FIL moderate-to-severe UC. Methods We...
Postoperative recurrence of Crohn's disease [POR-CD] is almost certain if no prophylaxis administered. Evidence for optimal treatment lacking. Our aim was to compare the efficacy adalimumab [ADA] and azathioprine [AZA] in this setting. We performed a phase 3, 52-week, multicentre, randomised, superiority study [APPRECIA], which patients with ileocolonic resection were randomised either ADA 160-80-40 mg subcutaneously [SC] or AZA 2.5 mg/kg/day, both associated metronidazole. The primary...
Summary Background The use of tumour necrosis factor antagonists has changed the therapeutic approach to Crohn's disease. Aim To determine response and remission rates associated with 4‐week induction phase adalimumab treatment in patients luminal and/or fistulizing disease, who have lost or become intolerant infliximab. Methods In this multicentre, prospective, open‐label, observational, 52‐week study, 50 adults received an dose (160 mg at baseline followed by 80 week 2). Results Of 36 83%...
Abstract Background Upadacitinib (UPA) has shown promising results in the pivotal trials, which require validation clinical practice. Primary aim:To assess durability of UPA treatment patients with ulcerative colitis (UC). Secondary aims:To short and long-term effectiveness, dose optimization response to dosage adjustments, impact extraintestinal manifestations (EIM) immunomediated diseases (IMIDs), tolerability UC a real-world setting Methods Adult who started for at least 8 weeks prior...
Abstract Background The addition of selective Janus kinase inhibitors (JAKi) –tofacitinib (TOFA), upadacitinib (UPA), and filgotinib (FILGO)– to the therapeutic arsenal for ulcerative colitis (UC) has provoked need comparative studies establish their positioning in clinical practice. Aim: To compare durability short- long-term effectiveness TOFA, UPA, FILGO UC, evaluate real-world safety. Methods Adult patients who started JAKi treatment UC (from April 2021) at least 8 weeks prior data...
Abstract Background Upadacitinib (UPA) is the first oral JAK inhibitor approved for treatment of Crohn's disease (CD). While its effectiveness and safety are well-documented in pivotal clinical trials, real-world data remain limited. Aim: To evaluate efficacy UPA both short long term CD patients. Methods A multicentre, prospective, observational study was conducted on patients receiving since approval. Epidemiological, disease-related variables, cardiovascular risk factors (CVRF) prior...
Abstract Background Colectomy is the primary treatment for dysplastic lesions in inflammatory bowel disease (IBD). Since development of advanced endoscopic techniques, management dysplasia evolving. Endoscopic submucosal resection (ESD) could be used selected cases at referral centres as an alternative to colectomy. However, feasibility and safety IBD remains limited. Main aim: To evaluate en-bloc rate need colectomy due ESD failure IBD. Secondary aims: assess complications ESD, local...
Abstract Background Phase III trials have demonstrated the efficacy of risankizumab (RZB), this being first humanized monoclonal IgG1 antibody which targets interleukin 23 p19 subunit, in Crohn’s disease (CD). However, real-world data with drug is limited. The aim our study was to assess effectiveness RZB patients CD. Methods Adult CD that had received treatment ENEIDA registry —a large prospectively maintained Spanish database promoted by Working Group and Colitis (GETECCU)— were included....
Abstract Background Although the concept of postoperative recurrence (POR) in Crohn’s disease (CD) has been limited to patients undergoing intestinal resection with anastomosis, some small-sized retrospective series short follow-up periods suggest that clinical POR may occur up 30% a definitive ostomy. This explain lack recommendations for monitoring and preventive strategies this setting. Our aim was assess risk current population. Methods Retrospective study from ENEIDA database GETECCU....
Abstract Background and Aims Inflammatory bowel disease (IBD) is a prevalent chronic noncurable associated with profound metabolic changes. The discovery of novel molecular indicators for unraveling IBD etiopathogenesis the diagnosis prognosis therefore pivotal. We sought to determine distinctive signatures from different subgroups before treatment initiation. Methods Serum urine samples newly diagnosed treatment-naïve patients age sex-matched healthy control (HC) individuals were...
Introduction . Persistent radiation-induced proctitis and rectal bleeding are debilitating complications with limited therapeutic options. We present our experience ozone therapy in the management of such refractory bleeding. Methods Patients (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>12</mml:mn></mml:math>) previously irradiated for prostate cancer persistent or severe without response to conventional treatment were enrolled...
Objectives: Mobile apps are useful tools in e-health and self-management strategies disease monitoring. We evaluated the Harvey–Bradshaw index (HBI) mobile app self-administered by patient to see if its results agreed with HBI in-clinic assessed a physician. Methods: Patients were enrolled 4-month prospective study clinical assessments at months 1 4. completed within 48 h, was performed physician (gold standard). scores characterized Crohn's (CD) as remission <5 or active ≥5. determined...
Summary Background Ustekinumab is approved for ulcerative colitis (UC). Aims To assess the durability of ustekinumab in patients with UC and its short‐term effectiveness, tolerability clinical practice. Methods Retrospective, multicentre study who had received their first dose at least 16 weeks before inclusion. Patients were followed until treatment discontinuation or last visit. Only active disease start considered effectiveness analysis. stopped visit not to be subsequent remission....
Beclometasone dipropionate (BDP) is a relatively new topically acting oral steroid to treat mild moderately active ulcerative colitis (UC). We estimate that 20,000 patients have received BDP in Spain the last two years. Our aim was evaluate efficacy and safety of clinical practice.Retrospective multicenter study included 434 with UC treated BDP. The partial Mayo Clinic score (pMS, 0-9) used measure disease activity. Remission defined as post-treatment pMS 0 or 1; response decrease 3 points 2...